Orphan Drugs Market Growth Rate, Industry Insights and Forecast 2024-2032

Global Orphan Drugs Market Growth Rate, Pipeline Trends, Industry Insights, and Forecast 2024-2032

<h2>Orphan Drugs Market Size</h2><blockquote>The Global Orphan Drugs Market reached US$ 223.76billion in 2023 and is expected to reach US$ 486.51 billion by 2032, growing at a CAGR of 9.1% during the forecast period 2024-2032.</blockquote>Orphan drugs&nbsp;are the medication indicated to treat, prevent, or diagnose an orphan disease. As per the U.S. Food and Drug Administration (FDA), orphan disease is a rare condition with less than 200,000 patients in the country. According to the European Medicine Agency, a disease is defined as rare if it affects fewer than 5 in 10,000 people across the European Union.The World Health Organization defines a rare disease or an orphan disease as one that affects fewer than 65 per 100,000 people. As per Orphanet, orphan designation is a legal procedure that allows for the designation of a medicinal substance with therapeutic potential for a rare disease, before its first administration in humans or during its clinical development.However, Developing orphan drugs is less financially attractive for pharmaceutical companies due to the limited patient size, and less market potential. To encourage the development of these novel therapies, governments and regulatory bodies across the globe offer incentives like tax credits, market exclusivity, and expedited regulatory approval.<h2>Executive Summary</h2><figure class="image"><img style="aspect-ratio:1061/639;" src="https://msbs-dmi-img.s3.eu-west-2.amazonaws.com/bucketFolder/1735292217587-lg.png" width="1061" height="639"></figure>For more details on this report – <a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/download-sample/orphan-drugs-market">Request for Sample</a>&nbsp;<h2>Market Dynamics: Drivers &amp; Restraints</h2>Rising Novel Drug Development Activities and Orphan Drug DesignationsAs the demand for advanced therapeutics continues to rise among patients with rare diseases, manufacturers are actively involved in developing these novel drugs to cater to the high unmet needs. The regulatory bodies across the world have been continually supporting the manufacturers considering the high unmet needs, and providing orphan drug designations and accelrated approvals to these new drugs.For instance, in February 2024, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for olezarsen developed by Ionis Pharmaceuticals, Inc. Olezarsen is an investigational drug aimed at the treatment of familial chylomicronemia syndrome (FCS) which is a rare, genetic disease characterized by extremely elevated triglyceride levels and recurrent acute pancreatitis (AP). Ionis states that If approved, olezarsen has the potential to be the standard of care in the U.S. for the treatment of FCS. In January 2023, the drug has already received Fast Track Designation from the U.S. FDA.Moreover, in October 2024, Kind Pharmaceuticals LLC announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AND017 in the treatment of Sickle Cell Disease (SCD). AND017 is a first-in-class hemoglobin-elevating agent that targets multiple stages of the red blood cell (RBC) life cycle. Kind Pharmaceuticals states that the orphan drug designation to AND017 underscores the urgent medical need for new therapies, particularly oral drugs to safely and effectively treat patients with SCD.These increasing Product development activities and orphan drug designations are expected to create significant traction in various therapeutic areas with high unmet needs and propel the overall market growth.The high cost of orphan drugs may restrain the market growth.Orphan drugs, although revolutionizing the treatment scenario for several rare diseases, their high cost may restrain the adoption rate, especially among low to middle-income patients. For instance, as per Drugs.com the list price of Spinraza is $750,000 for the first year and then $350,000 in later years. Spinraza is an alternative drug to Zolgensma for the treatment of patients with spinal muscular atrophy (SMA). The same drug costs approximately INR 7 million in India, where the majority of the patients lack proper medical insurance.&nbsp;<h2>Market Segment Analysis</h2>The global orphan drugs market is&nbsp;segmented based on product type, therapy area, and region.Oncology is dominating the therapy area segment of the orphan drugs market with the highest market share.Oncology is the most widely explored indication for orphan drugs, due to high unmet needs for various types of rare cancers. Majority of the current approved orphan drugs are aimed for rare cancer treatments. For instance below is the list of top-selling orphan drugs with different types of cancers as their major indications. The top 5 selling orphan drugs for oncology accounted for nearly US$24.2 billion in 2023.&nbsp;<figure class="table"><table><tbody><tr><td>Sr. No</td><td>Drug</td><td>Indication</td><td>Sales Value (2023) in Milion</td></tr><tr><td>1</td><td>Darzalex</td><td>Multiple Myeloma</td><td>9,744.00</td></tr><tr><td>2</td><td>Imbruvica</td><td>Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)</td><td>6,860.00</td></tr><tr><td>3</td><td>Lynparza</td><td>Multiple Cancers</td><td>2,811.00</td></tr><tr><td>4</td><td>Calquence</td><td>Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)</td><td>2,514.00</td></tr><tr><td>5</td><td>Venclexta</td><td>Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL), Acute Myeloid Leukemia (AML)</td><td>2,288.00</td></tr></tbody></table></figure><h2>Market Geographical Share</h2>North America is expected to hold a significant share of the orphan drugs market.North America dominates the market for orphan drugs and is expected to show a similar trend over the forecast period. The factors contributing to the region’s dominance include the advanced healthcare system, government initiatives, and the strong presence of many market players. The FDA Office of Orphan Products Development approves orphan drug designation for novel drugs and biologics that are used for the safe and effective treatment, diagnosis, and prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States. The designation allows key players to qualify for various incentives, including tax credits for qualified clinical trials and, upon regulatory approval, 7 years of market exclusivity.Moreover, all the manufacturers of orphan drugs majorly operate in the region, generating higher sales, especially from the U.S. Below is the list of top 5 selling orphan drugs and their revenue share from the U.S.<figure class="table"><table><tbody><tr><td>Sr. No</td><td>Drug</td><td>Sales Value (2023) in Milion</td><td>U.S. Share</td></tr><tr><td>1</td><td>Darzalex</td><td>9,744.00</td><td>54.16%</td></tr><tr><td>2</td><td>Trikafta/Kaftrio</td><td>8,944.70</td><td>61.20%</td></tr><tr><td>3</td><td>Imbruvica Total</td><td>6,860.00</td><td>54.17%</td></tr><tr><td>4</td><td>Lynparza</td><td>2,811.00</td><td>44.61%</td></tr><tr><td>5</td><td>Calquence</td><td>2,514.00</td><td>72.20%</td></tr></tbody></table></figure>&nbsp;This represents the dominance of North America, especially the U.S. in the global market for orphan drugs.<h2>Competitive Landscape</h2>The major global players in the orphan drugs market&nbsp;are Johnson &amp; Johnson Services, Inc., AbbVie Inc., Vertex Pharmaceuticals Incorporated, AstraZeneca., Incyte., Biogen., Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., and Bristol-Myers Squibb Company among others.&nbsp;<h2>Key Developments</h2><ul><li>In October 2024, Can-Fite BioPharma Ltd. Announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for Namodenoson which is indicated for the treatment of pancreatic cancer.</li><li>In April 2024, the European Commission granted orphan medicinal product designation for Zatolmilast developed by Shionogi &amp; Co., Ltd. Zatolmilast is the investigational drug for the treatment of Fragile X syndrome (FXS), which is a leading cause of inherited intellectual disability and autism.</li></ul><h2>Emerging Players&nbsp;</h2>The emerging players in the orphan drugs market include Can-Fite, Mustang Bio, Kind Pharmaceuticals LLC, Cabaletta Bio, Inc. and Ionis Pharmaceuticals, Inc. among others.<figure class="table"><table><tbody><tr><td>Metrics</td><td colspan="2">Details</td></tr><tr><td>CAGR</td><td colspan="2">9.1%</td></tr><tr><td>Market Size Available for Years</td><td colspan="2">2022-2032</td></tr><tr><td>Estimation Forecast Period</td><td colspan="2">2024-2032</td></tr><tr><td>Revenue Units</td><td colspan="2">Value (US$ Mn)&nbsp;</td></tr><tr><td rowspan="2">Segments Covered</td><td>Product Type</td><td>Small Molecules, Biologic Drugs, Others</td></tr><tr><td>Therapy Area</td><td>Oncology, Hematology Diseases, Central Nervous System, Cardiovascular, Endocrine, Respiratory, Immunologic Conditions, Gastro-Intestinal, Musculoskeletal, Dermatology and Others</td></tr><tr><td>Regions Covered</td><td colspan="2">North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa</td></tr></tbody></table></figure>Why Purchase the Report?<ul><li>Pipeline &amp; Innovations:&nbsp;Reviews ongoing clinical trials, and Product Type pipelines, and forecasts upcoming pharmaceutical advancements.</li><li>Product Type Performance &amp; Market Positioning:&nbsp;Analyzes Product Type performance, market positioning, and growth potential to optimize strategies.</li><li>Real-World Evidence:&nbsp;Integrates patient feedback and data into Product Type development for improved outcomes.</li><li>Physician Preferences &amp; Health System Impact:&nbsp;Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.</li><li>Market Updates &amp; Industry Changes:&nbsp;Covers recent regulatory changes, new policies, and emerging technologies.</li><li>Competitive Strategies:&nbsp;Analyzes competitor strategies, market share, and emerging players.</li><li>Pricing &amp; Market Access:&nbsp;Reviews pricing models, reimbursement trends, and market access strategies.</li><li>Market Entry &amp; Expansion:&nbsp;Identifies optimal strategies for entering new markets and partnerships.</li><li>Regional Growth &amp; Investment:&nbsp;Highlights high-growth regions and investment opportunities.</li><li>Supply Chain Optimization:&nbsp;Assesses supply chain risks and distribution strategies for efficient Product Type delivery.</li><li>Sustainability &amp; Regulatory Impact:&nbsp;Focuses on eco-friendly practices and evolving regulations in healthcare.</li><li>Post-market Surveillance:&nbsp;Uses post-market data to enhance Product Type safety and access.</li><li>Pharmacoeconomics &amp; Value-Based Pricing:&nbsp;Analyzes the shift to value-based pricing and data-driven decision-making in R&amp;D.</li></ul>&nbsp;The global&nbsp;Orphan drugs market report would provide approximately 54 tables, 50 figures, and 179 pages.&nbsp;Target Audience 2024<ul><li>Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.</li><li>Regulatory &amp; Policy:&nbsp;Compliance Officers, Government, Health Economists, Market Access Specialists.</li><li>Technology &amp; Innovation:&nbsp;R&amp;D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.</li><li>Investors:&nbsp;Healthcare Investors, Venture Fund Investors, Pharma Marketing &amp; Sales.</li><li>Consulting &amp; Advisory:&nbsp;Healthcare Consultants, Industry Associations, Analysts.</li><li>Supply Chain:&nbsp;Distribution and Supply Chain Managers.</li><li>Consumers &amp; Advocacy:&nbsp;Patients, Advocacy Groups, Insurance Companies.</li><li>Academic &amp; Research:&nbsp;Academic Institutions.</li></ul>&nbsp;&nbsp;

&nbsp;<ol><li><h3><a>Methodology and Scope</a></h3><ol><li>Research Methodology</li><li>Research Objective and Scope of the Report</li></ol></li><li><h3>Definition and Overview</h3></li><li><h3>Executive Summary</h3><ol><li>Snippet by Product Type</li><li>Snippet by Therapy Area</li><li>Snippet by Region</li></ol></li><li><h3>Dynamics</h3><ol><li>Impacting Factors<ol><li>Drivers<ol><li>Rising Novel Drug Development Activities and Orphan Drug Designations</li><li>Rising Demand from Unmet Population with Rare Diseases</li></ol></li><li>Restraints<ol><li>High Cost of Treatment</li><li>XX</li></ol></li><li>Opportunities</li></ol></li></ol></li><li>Impact Analysis</li><li><h3>Industry Analysis&nbsp;</h3><ol><li>Porter’s Five Force Analysis</li><li>Supply Chain Analysis</li><li>Epidemiology</li><li>Pricing Analysis</li><li>Pipeline Analysis</li><li>Patent Analysis</li><li>Regulatory Analysis</li></ol></li><li><h3>By Product Type&nbsp;</h3><ol><li>Introduction<ol><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li><li>Market Attractiveness Index, By Product Type</li></ol></li><li>Small Molecules*<ol><li>Introduction</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li></ol></li><li>Biologic Drugs<ol><li>Gene Therapies</li><li>Monoclonal Antibodies</li><li>Others</li></ol></li><li>Others</li></ol></li><li><h3>By Therapy Area</h3><ol><li>Introduction<ol><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area</li><li>Market Attractiveness Index, By Therapy Area</li></ol></li><li>Oncology*<ol><li>Introduction</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li></ol></li><li>Hematology Diseases</li><li>Central Nervous System</li><li>Cardiovascular</li><li>Endocrine</li><li>Respiratory</li><li>Immunologic Conditions</li><li>Gastro-Intestinal</li><li>Musculoskeletal</li><li>Dermatology</li><li>Others</li></ol></li><li><h3>By Region</h3><ol><li>Introduction<ol><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li><li>Market Attractiveness Index, By Region</li></ol></li><li>North America<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country<ol><li>U.S.</li><li>Canada</li><li>Mexico</li></ol></li></ol></li><li>Europe<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country<ol><li>Germany</li><li>U.K.</li><li>France</li><li>Spain</li><li>Italy</li><li>Rest of Europe</li></ol></li></ol></li><li>South America<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country<ol><li>Brazil</li><li>Argentina</li><li>Rest of South America</li></ol></li></ol></li><li>Asia-Pacific<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country<ol><li>China</li><li>India</li><li>Japan</li><li>South Korea</li><li>Rest of Asia-Pacific</li></ol></li></ol></li><li>Middle East and Africa<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li><li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Area</li></ol></li></ol></li><li><h3>Competitive Landscape</h3><ol><li>Competitive Scenario</li><li>Market Positioning/Share Analysis</li><li>Mergers and Acquisitions Analysis</li></ol></li><li><h3>Company Profiles</h3><ol><li>Johnson &amp; Johnson Services, Inc.*<ol><li>Company Overview</li><li>Product Type Portfolio and Description</li><li>Financial Overview</li><li>Key Developments</li></ol></li><li>AbbVie Inc.</li><li>Vertex Pharmaceuticals Incorporated</li><li>AstraZeneca.</li><li>Incyte.</li><li>Biogen.</li><li>Novartis AG</li><li>F. Hoffmann-La Roche Ltd</li><li>Pfizer Inc.</li><li>Bristol-Myers Squibb Company (LIST NOT EXHAUSTIVE )</li></ol></li><li><h3>Appendix</h3><ol><li>About Us and Services</li><li>Contact Us</li></ol></li></ol>Suggestions for Related Report<ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/research-report/cell-and-gene-therapy-market">Cell and Gene Therapy Market</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/research-report/biologic-therapeutics-drugs-market">Biologic Therapeutics Drugs Market</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/research-report/rare-neurological-disease-drugs-market">Rare Neurological Disease Drugs Market</a></li></ul>For more pharmaceuticals-related reports,&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/industry-verticals/pharmaceuticals">please click here</a>

List of TablesTable 1 Global Orphan Drugs Market Value, By Product Type, 2024, 2028 &amp; 2032 (US$ Million)Table 2 Global Orphan Drugs Market Value, By Therapy Area, 2024, 2028 &amp; 2032 (US$ Million)Table 3 Global Orphan Drugs Market Value, By Region, 2024, 2028 &amp; 2032 (US$ Million)Table 4 Global Orphan Drugs Market Value, By Product Type, 2024, 2028 &amp; 2032 (US$ Million)Table 5 Global Orphan Drugs Market Value, By Product Type, 2023-2032 (US$ Million)Table 6 Global Orphan Drugs Market Value, By Therapy Area, 2024, 2028 &amp; 2032 (US$ Million)Table 7 Global Orphan Drugs Market Value, By Therapy Area, 2023-2032 (US$ Million)Table 8 Global Orphan Drugs Market Value, By Region, 2024, 2028 &amp; 2032 (US$ Million)Table 9 Global Orphan Drugs Market Value, By Region, 2023-2032 (US$ Million)Table 10 North America Orphan Drugs Market Value, By Product Type, 2023-2032 (US$ Million)Table 11 North America Orphan Drugs Market Value, By Therapy Area, 2023-2032 (US$ Million)Table 12 North America Orphan Drugs Market Value, By Country, 2023-2032 (US$ Million)Table 13 South America Orphan Drugs Market Value, By Product Type, 2023-2032 (US$ Million)Table 14 South America Orphan Drugs Market Value, By Therapy Area, 2023-2032 (US$ Million)Table 15 South America Orphan Drugs Market Value, By Country, 2023-2032 (US$ Million)Table 16 Europe Orphan Drugs Market Value, By Product Type, 2023-2032 (US$ Million)Table 17 Europe Orphan Drugs Market Value, By Therapy Area, 2023-2032 (US$ Million)Table 18 Europe Orphan Drugs Market Value, By Country, 2023-2032 (US$ Million)Table 19 Asia-Pacific Orphan Drugs Market Value, By Product Type, 2023-2032 (US$ Million)Table 20 Asia-Pacific Orphan Drugs Market Value, By Therapy Area, 2023-2032 (US$ Million)Table 21 Asia-Pacific Orphan Drugs Market Value, By Country, 2023-2032 (US$ Million)Table 22 Middle East and Africa Orphan Drugs Market Value, By Product Type, 2023-2032 (US$ Million)Table 23 Middle East and Africa Orphan Drugs Market Value, By Therapy Area, 2023-2032 (US$ Million)Table 24 Middle East and Africa Orphan Drugs Market Value, By Country, 2023-2032 (US$ Million)Table 25 Johnson &amp; Johnson Services, Inc.: OverviewTable 26 Johnson &amp; Johnson Services, Inc.: Product PortfolioTable 27 Johnson &amp; Johnson Services, Inc.: Key DevelopmentsTable 28 AbbVie Inc.: OverviewTable 29 AbbVie Inc.: Product PortfolioTable 30 AbbVie Inc.: Key DevelopmentsTable 31 Vertex Pharmaceuticals Incorporated: OverviewTable 32 Vertex Pharmaceuticals Incorporated: Product PortfolioTable 33 Vertex Pharmaceuticals Incorporated: Key DevelopmentsTable 34 AstraZeneca.: OverviewTable 35 AstraZeneca.: Product PortfolioTable 36 AstraZeneca.: Key DevelopmentsTable 37 Incyte.: OverviewTable 38 Incyte.: Product PortfolioTable 39 Incyte.: Key DevelopmentsTable 40 Biogen.: OverviewTable 41 Biogen.: Product PortfolioTable 42 Biogen.: Key DevelopmentsTable 43 Novartis AG: OverviewTable 44 Novartis AG: Product PortfolioTable 45 Novartis AG: Key DevelopmentsTable 46 F. Hoffmann-La Roche Ltd: OverviewTable 47 F. Hoffmann-La Roche Ltd: Product PortfolioTable 48 F. Hoffmann-La Roche Ltd: Key DevelopmentsTable 49 Pfizer Inc.: OverviewTable 50 Pfizer Inc.: Product PortfolioTable 51 Pfizer Inc.: Key DevelopmentsTable 52 Bristol-Myers Squibb Company: OverviewTable 53 Bristol-Myers Squibb Company: Product PortfolioTable 54 Bristol-Myers Squibb Company: Key DevelopmentsList of FiguresFigure 1 Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 2 Global Orphan Drugs Market Share, By Product Type, 2024 &amp; 2032 (%)Figure 3 Global Orphan Drugs Market Share, By Therapy Area, 2024 &amp; 2032 (%)Figure 4 Global Orphan Drugs Market Share, By Region, 2024 &amp; 2032 (%)Figure 5 Global Orphan Drugs Market Y-o-Y Growth, By Product Type, 2024-2032 (%)Figure 6 Small Molecules Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 7 Biologic Drugs Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 8 Others Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 9 Global Orphan Drugs Market Y-o-Y Growth, By Therapy Area, 2024-2032 (%)Figure 10 Oncology Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 11 Hematology Diseases Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 12 Central Nervous System Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 13 Cardiovascular Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 14 Endocrine Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 15 Respiratory Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 16 Immunologic Conditions Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 17 Gastro-Intestinal Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 18 Musculoskeletal Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 19 Dermatology Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 20 Others Therapy Area in Global Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 21 Global Orphan Drugs Market Y-o-Y Growth, By Region, 2024-2032 (%)Figure 22 North America Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 23 North America Orphan Drugs Market Share, By Product Type, 2024 &amp; 2032 (%)Figure 24 North America Orphan Drugs Market Share, By Therapy Area, 2024 &amp; 2032 (%)Figure 25 North America Orphan Drugs Market Share, By Country, 2024 &amp; 2032 (%)Figure 26 South America Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 27 South America Orphan Drugs Market Share, By Product Type, 2024 &amp; 2032 (%)Figure 28 South America Orphan Drugs Market Share, By Therapy Area, 2024 &amp; 2032 (%)Figure 29 South America Orphan Drugs Market Share, By Country, 2024 &amp; 2032 (%)Figure 30 Europe Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 31 Europe Orphan Drugs Market Share, By Product Type, 2024 &amp; 2032 (%)Figure 32 Europe Orphan Drugs Market Share, By Therapy Area, 2024 &amp; 2032 (%)Figure 33 Europe Orphan Drugs Market Share, By Country, 2024 &amp; 2032 (%)Figure 34 Asia-Pacific Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 35 Asia-Pacific Orphan Drugs Market Share, By Product Type, 2024 &amp; 2032 (%)Figure 36 Asia-Pacific Orphan Drugs Market Share, By Therapy Area, 2024 &amp; 2032 (%)Figure 37 Asia-Pacific Orphan Drugs Market Share, By Country, 2024 &amp; 2032 (%)Figure 38 Middle East and Africa Orphan Drugs Market Value, 2023-2032 (US$ Million)Figure 39 Middle East and Africa Orphan Drugs Market Share, By Product Type, 2024 &amp; 2032 (%)Figure 40 Middle East and Africa Orphan Drugs Market Share, By Therapy Area, 2024 &amp; 2032 (%)Figure 41 Johnson &amp; Johnson Services, Inc.: FinancialsFigure 42 AbbVie Inc.: FinancialsFigure 43 Vertex Pharmaceuticals Incorporated: FinancialsFigure 44 AstraZeneca.: FinancialsFigure 45 Incyte.: FinancialsFigure 46 Biogen.: FinancialsFigure 47 Novartis AG: FinancialsFigure 48 F. Hoffmann-La Roche Ltd: FinancialsFigure 49 Pfizer Inc.: FinancialsFigure 50 Bristol-Myers Squibb Company: Financials

Orphan Drugs Market is segmented by Product Type (Small Molecules, Biologic Drugs [Gene Therapies, Monoclonal Antibodies, Others], Others), and by Therapy Area (Oncology, Hematology Diseases, Central Nervous System, Cardiovascular, Endocrine, Respiratory, Immunologic Conditions, Gastro-Intestinal, Musculoskeletal, Dermatology, Others),), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)